2017 | 2016 | 2015 | 2014
DateTitle 
February 15, 2017Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo
INDIANAPOLIS ,Feb. 15, 2017/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) – were published in the New England Journal of Medicine.The New England Journal of Medicine publication includes supplementary data, which show that starting as early as week 8, and sustained through week 52, a h... 
Printer Friendly Version
February 14, 2017Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs
$238 million of 2016 fourth-quarter net product revenues from Jakafi® (ruxolitinib), representing 30 percent growth over the same period last year and $853 million of 2016 full-year net product revenues from Jakafi, representing 42 percent growth over last year Multiple pivotal programs expected to commence this year, including the combination of epacadostat and pembrolizumab in four additional solid tumor indications ... 
Printer Friendly Version
February 14, 2017Incyte and Agenus Amend Collaboration Agreement
Incyte secures global clinical development and commercialization responsibilities for GITR and OX40 programs, converting both from profit-sharing to royalty-bearing arrangements Agenus to receive $80 million from Incyte: $60 million equity investment at $6 per share and $20 million in accelerated clinical development milestones WILMINGTON, Del. & LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 14, 2017-- Incyte Corporation (Nasdaq:INCY) an... 
Printer Friendly Version
February 13, 2017European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU INDIANAPOLIS, Feb. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Commission has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or w... 
Printer Friendly Version
January 30, 2017Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
Incyte gains worldwide rights to CB-1158 for hematology and oncology indications Calithera to receive a $45 million up-front payment and an $8 million equity investment Incyte and Calithera to co-fund global development of CB-1158; Calithera eligible to receive share of profits in the U.S., potential milestones and royalties on future sales of CB-1158 Calithera conference call scheduled... 
Printer Friendly Version
January 24, 2017Incyte to Report Fourth Quarter and Year-End Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 24, 2017-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter and year end 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, February 14, 2017. The schedule for the press release and conference call/webcast is as follows:      ... 
Printer Friendly Version
January 13, 2017U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment
INDIANAPOLIS, Jan. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis (RA). The NDA for baricitinib was submitted to the FDA in January 2016.The FDA extended the action date to allow time to review ... 
Printer Friendly Version
January 09, 2017Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)
Additional pivotal studies evaluating Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017 WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jan. 9, 2017-- Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical de... 
Printer Friendly Version
RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet